Business
DraftKings’ expensive bet on prediction markets is crushing its stock
By Katherine Langford
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Katherine Langford
Katherine Langford
Editor-in-Chief · Edina, MN
Katherine oversees editorial operations across all six brands. Before joining The Meridan Group, she spent 14 years at the Minneapolis Star Tribune, where she led the metro desk through its digital transformation. She holds a Master's in Journalism from Northwestern's Medill School.
More from Katherine →Editor-in-Chief · Friday, November 6, 2026 at 4:29 PM · 1 min read
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Up nextDraftKings’ expensive bet on prediction markets is crushing its stockBusiness · 1 min read
More Business stories
Business
Two months after my father’s funeral, my stepmother asked me to repay his $40,000 wedding gift. Should I do what she says?
By Marcus Chen
Business
‘We’re losing to cottage cheese’: The protein-maxxing craze is hurting cream cheese sales
By Katherine Langford
Business
These three stars need to align before investors rush back into stocks, Bank of America strategist says
By Marcus Chen